Cargando…
Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library
Lyme disease is a leading vector-borne disease in the United States. Although the majority of Lyme patients can be cured with standard 2–4 week antibiotic treatment, 10%–20% of patients continue to suffer from prolonged post-treatment Lyme disease syndrome (PTLDS). While the cause for this is unclea...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790293/ https://www.ncbi.nlm.nih.gov/pubmed/27025631 http://dx.doi.org/10.3390/antibiotics4030397 |
_version_ | 1782420967452049408 |
---|---|
author | Feng, Jie Weitner, Megan Shi, Wanliang Zhang, Shuo Sullivan, David Zhang, Ying |
author_facet | Feng, Jie Weitner, Megan Shi, Wanliang Zhang, Shuo Sullivan, David Zhang, Ying |
author_sort | Feng, Jie |
collection | PubMed |
description | Lyme disease is a leading vector-borne disease in the United States. Although the majority of Lyme patients can be cured with standard 2–4 week antibiotic treatment, 10%–20% of patients continue to suffer from prolonged post-treatment Lyme disease syndrome (PTLDS). While the cause for this is unclear, persisting organisms not killed by current Lyme antibiotics may be involved. In our previous study, we screened an FDA drug library and reported 27 top hits that showed high activity against Borrelia persisters. In this study, we present the results of an additional 113 active hits that have higher activity against the stationary phase B. burgdorferi than the currently used Lyme antibiotics. Many antimicrobial agents (antibiotics, antivirals, antifungals, anthelmintics or antiparasitics) used for treating other infections were found to have better activity than the current Lyme antibiotics. These include antibacterials such as rifamycins (3-formal-rifamycin, rifaximin, rifamycin SV), thiostrepton, quinolone drugs (sarafloxacin, clinafloxacin, tosufloxacin), and cell wall inhibitors carbenicillin, tazobactam, aztreonam; antifungal agents such as fluconazole, mepartricin, bifonazole, climbazole, oxiconazole, nystatin; antiviral agents zanamivir, nevirapine, tilorone; antimalarial agents artemisinin, methylene blue, and quidaldine blue; antihelmintic and antiparasitic agents toltrazuril, tartar emetic, potassium antimonyl tartrate trihydrate, oxantel, closantel, hycanthone, pyrimethamine, and tetramisole. Interestingly, drugs used for treating other non-infectious conditions including verteporfin, oltipraz, pyroglutamic acid, pidolic acid, and dextrorphan tartrate, that act on the glutathione/γ-glutamyl pathway involved in protection against free radical damage, and also the antidepressant drug indatraline, were found to have high activity against stationary phase B. burgdorferi. Among the active hits, agents that affect cell membranes, energy production, and reactive oxygen species production are more active against the B. burgdorferi persisters than the commonly used antibiotics that inhibit macromolecule biosynthesis. Future studies are needed to evaluate and optimize the promising active hits in drug combination studies in vitro and also in vivo in animal models. These studies may have implications for developing more effective treatments of Lyme disease. |
format | Online Article Text |
id | pubmed-4790293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-47902932016-03-24 Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library Feng, Jie Weitner, Megan Shi, Wanliang Zhang, Shuo Sullivan, David Zhang, Ying Antibiotics (Basel) Article Lyme disease is a leading vector-borne disease in the United States. Although the majority of Lyme patients can be cured with standard 2–4 week antibiotic treatment, 10%–20% of patients continue to suffer from prolonged post-treatment Lyme disease syndrome (PTLDS). While the cause for this is unclear, persisting organisms not killed by current Lyme antibiotics may be involved. In our previous study, we screened an FDA drug library and reported 27 top hits that showed high activity against Borrelia persisters. In this study, we present the results of an additional 113 active hits that have higher activity against the stationary phase B. burgdorferi than the currently used Lyme antibiotics. Many antimicrobial agents (antibiotics, antivirals, antifungals, anthelmintics or antiparasitics) used for treating other infections were found to have better activity than the current Lyme antibiotics. These include antibacterials such as rifamycins (3-formal-rifamycin, rifaximin, rifamycin SV), thiostrepton, quinolone drugs (sarafloxacin, clinafloxacin, tosufloxacin), and cell wall inhibitors carbenicillin, tazobactam, aztreonam; antifungal agents such as fluconazole, mepartricin, bifonazole, climbazole, oxiconazole, nystatin; antiviral agents zanamivir, nevirapine, tilorone; antimalarial agents artemisinin, methylene blue, and quidaldine blue; antihelmintic and antiparasitic agents toltrazuril, tartar emetic, potassium antimonyl tartrate trihydrate, oxantel, closantel, hycanthone, pyrimethamine, and tetramisole. Interestingly, drugs used for treating other non-infectious conditions including verteporfin, oltipraz, pyroglutamic acid, pidolic acid, and dextrorphan tartrate, that act on the glutathione/γ-glutamyl pathway involved in protection against free radical damage, and also the antidepressant drug indatraline, were found to have high activity against stationary phase B. burgdorferi. Among the active hits, agents that affect cell membranes, energy production, and reactive oxygen species production are more active against the B. burgdorferi persisters than the commonly used antibiotics that inhibit macromolecule biosynthesis. Future studies are needed to evaluate and optimize the promising active hits in drug combination studies in vitro and also in vivo in animal models. These studies may have implications for developing more effective treatments of Lyme disease. MDPI 2015-09-16 /pmc/articles/PMC4790293/ /pubmed/27025631 http://dx.doi.org/10.3390/antibiotics4030397 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Feng, Jie Weitner, Megan Shi, Wanliang Zhang, Shuo Sullivan, David Zhang, Ying Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library |
title | Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library |
title_full | Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library |
title_fullStr | Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library |
title_full_unstemmed | Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library |
title_short | Identification of Additional Anti-Persister Activity against Borrelia burgdorferi from an FDA Drug Library |
title_sort | identification of additional anti-persister activity against borrelia burgdorferi from an fda drug library |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790293/ https://www.ncbi.nlm.nih.gov/pubmed/27025631 http://dx.doi.org/10.3390/antibiotics4030397 |
work_keys_str_mv | AT fengjie identificationofadditionalantipersisteractivityagainstborreliaburgdorferifromanfdadruglibrary AT weitnermegan identificationofadditionalantipersisteractivityagainstborreliaburgdorferifromanfdadruglibrary AT shiwanliang identificationofadditionalantipersisteractivityagainstborreliaburgdorferifromanfdadruglibrary AT zhangshuo identificationofadditionalantipersisteractivityagainstborreliaburgdorferifromanfdadruglibrary AT sullivandavid identificationofadditionalantipersisteractivityagainstborreliaburgdorferifromanfdadruglibrary AT zhangying identificationofadditionalantipersisteractivityagainstborreliaburgdorferifromanfdadruglibrary |